Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides. 1999

J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
Infectious Diseases Research Laboratory, Hospital General Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. gavalda@hg.vhebron.es

The purpose of this work was to evaluate the in vitro possibilities of ampicillin-ceftriaxone combinations for 10 Enterococcus faecalis strains with high-level resistance to aminoglycosides (HLRAg) and to assess the efficacy of ampicillin plus ceftriaxone, both administered with humanlike pharmacokinetics, for the treatment of experimental endocarditis due to HLRAg E. faecalis. A reduction of 1 to 4 dilutions in MICs of ampicillin was obtained when ampicillin was combined with a fixed subinhibitory ceftriaxone concentration of 4 micrograms/ml. This potentiating effect was also observed by the double disk method with all 10 strains. Time-kill studies performed with 1 and 2 micrograms of ampicillin alone per ml or in combination with 5, 10, 20, 40, and 60 micrograms of ceftriaxone per ml showed a > or = 2 log10 reduction in CFU per milliliter with respect to ampicillin alone and to the initial inoculum for all 10 E. faecalis strains studied. This effect was obtained for seven strains with the combination of 2 micrograms of ampicillin per ml plus 10 micrograms of ceftriaxone per ml and for six strains with 5 micrograms of ceftriaxone per ml. Animals with catheter-induced endocarditis were infected intravenously with 10(8) CFU of E. faecalis V48 or 10(5) CFU of E. faecalis V45 and were treated for 3 days with humanlike pharmacokinetics of 2 g of ampicillin every 4 h, alone or combined with 2 g of ceftriaxone every 12 h. The levels in serum and the pharmacokinetic parameters of the humanlike pharmacokinetics of ampicillin or ceftriaxone in rabbits were similar to those found in humans treated with 2 g of ampicillin or ceftriaxone intravenously. Results of the therapy for experimental endocarditis caused by E. faecalis V48 or V45 showed that the residual bacterial titers in aortic valve vegetations were significantly lower in the animals treated with the combinations of ampicillin plus ceftriaxone than in those treated with ampicillin alone (P < 0.001). The combination of ampicillin and ceftriaxone showed in vitro and in vivo synergism against HLRAg E. faecalis.

UI MeSH Term Description Entries
D007260 Infusion Pumps Fluid propulsion systems driven mechanically, electrically, or osmotically that are used to inject (or infuse) over time agents into a patient or experimental animal; used routinely in hospitals to maintain a patent intravenous line, to administer antineoplastic agents and other drugs in thromboembolism, heart disease, diabetes mellitus (INSULIN INFUSION SYSTEMS is also available), and other disorders. Drug Infusion Systems,Infusion Pump,Infusion Pumps, External,Infusors,Intravenous Drug Delivery System,Intravenous Drug Delivery Systems,Perfusion Pumps,Pumps, Infusion,Drug Infusion System,External Infusion Pump,External Infusion Pumps,Infusion Pump, External,Infusion System, Drug,Infusion Systems, Drug,Infusor,Perfusion Pump,Pump, External Infusion,Pump, Infusion,Pump, Perfusion,Pumps, External Infusion,Pumps, Perfusion,System, Drug Infusion,Systems, Drug Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D010406 Penicillins A group of antibiotics that contain 6-aminopenicillanic acid with a side chain attached to the 6-amino group. The penicillin nucleus is the chief structural requirement for biological activity. The side-chain structure determines many of the antibacterial and pharmacological characteristics. (Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1065) Antibiotics, Penicillin,Penicillin,Penicillin Antibiotics
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
February 2008, Annals of internal medicine,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
September 2003, The Journal of antimicrobial chemotherapy,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
August 2004, Journal of chemotherapy (Florence, Italy),
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
October 2021, Journal of clinical medicine,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
December 2021, Journal of clinical medicine,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
May 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
December 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
January 1997, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
February 2020, Infectious diseases (London, England),
J Gavaldà, and C Torres, and C Tenorio, and P López, and M Zaragoza, and J A Capdevila, and B Almirante, and F Ruiz, and N Borrell, and X Gomis, and C Pigrau, and F Baquero, and A Pahissa
October 1993, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!